🚨🇮🇷 IRAN EMERGED AS LEADING ASIAN DEVELOPER OF ELECTROCHEMOTHERAPY
Iran has developed Oncopore G2121, a domestically produced electrochemotherapy system equipped with proprietary probe technology.
The technology works by delivering precisely controlled electric pulses that increase the permeability of cancer cell membranes, enabling chemotherapy drugs to penetrate malignant cells at higher concentrations while minimizing damage to surrounding healthy tissue.
🔸 Iran has become one of only three countries in the world capable of producing this advanced cancer treatment device.
🔸 In May 2025, experts at Pars Pioneers in Therapeutic Technologies Company launched Iran's first domestic production line for electrochemotherapy devices.
🔸 Oncopore G2121 incorporates proprietary probe designs with no known foreign counterparts, delivering clinical outcomes validated in peer-reviewed international journals.
🔸 More than 2,000 patients have already been treated using the technology. Over 200 cases achieved successful outcomes that prevented the need for amputation.
🔸 The system costs approximately 40-50% less than comparable foreign systems, making advanced cancer treatment more accessible.
🔸 Clinical applications include cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, breast cancer, liver tumors, pancreatic tumors, and oral cavity lesions.
🔸A 100% overall response rate at one month has been reported, with 53 lesions achieving complete clinical response and 51 showing partial response.
🔸 Basal cell carcinoma showed notably higher complete response rates, with 96% of nodules achieving complete remission.
🔸 11 of 15 patients achieved complete remission, with a mean tumor area reduction of 90%. No patients developed tumor lysis syndrome.
Electrochemotherapy is changing how cancer is treated — it targets tumors directly, causes less damage to healthy tissue, and Iran now makes the technology itself.
Follow us on↗ Telegram 🤳 Instagram 🤖 Twitter
Iran has developed Oncopore G2121, a domestically produced electrochemotherapy system equipped with proprietary probe technology.
The technology works by delivering precisely controlled electric pulses that increase the permeability of cancer cell membranes, enabling chemotherapy drugs to penetrate malignant cells at higher concentrations while minimizing damage to surrounding healthy tissue.
🔸 Iran has become one of only three countries in the world capable of producing this advanced cancer treatment device.
🔸 In May 2025, experts at Pars Pioneers in Therapeutic Technologies Company launched Iran's first domestic production line for electrochemotherapy devices.
🔸 Oncopore G2121 incorporates proprietary probe designs with no known foreign counterparts, delivering clinical outcomes validated in peer-reviewed international journals.
🔸 More than 2,000 patients have already been treated using the technology. Over 200 cases achieved successful outcomes that prevented the need for amputation.
🔸 The system costs approximately 40-50% less than comparable foreign systems, making advanced cancer treatment more accessible.
🔸 Clinical applications include cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, breast cancer, liver tumors, pancreatic tumors, and oral cavity lesions.
🔸A 100% overall response rate at one month has been reported, with 53 lesions achieving complete clinical response and 51 showing partial response.
🔸 Basal cell carcinoma showed notably higher complete response rates, with 96% of nodules achieving complete remission.
🔸 11 of 15 patients achieved complete remission, with a mean tumor area reduction of 90%. No patients developed tumor lysis syndrome.
Electrochemotherapy is changing how cancer is treated — it targets tumors directly, causes less damage to healthy tissue, and Iran now makes the technology itself.
Follow us on
Please open Telegram to view this post
VIEW IN TELEGRAM
Please open Telegram to view this post
VIEW IN TELEGRAM
❤37👍16👏16👌1
This media is not supported in your browser
VIEW IN TELEGRAM
🚨🇷🇺 NATO IN PANIC: RUSSIA ARMS WORLD’S LARGEST CRUISER WITH SUBMARINE HUNTERS
The Russian cruiser ‘Admiral Nakhimov’ is now ready to destroy any enemy submarine threat, equipped with three Ka-27M anti-submarine helicopters, making the world’s largest surface combatant the non-aircraft-carrier warship with the largest airborne squadron of any in service.
🔸 The 28,000-ton Admiral Nakhimov remains the world’s largest surface combatant and the only one designed from the outset to carry three heavyweight Ka-27M helicopters in a below-deck hangar.
🔸 The modernized Ka-27M helicopters deliver real-time digital sensor fusion, the Kopye-A radar for extended-range multi-target tracking, and advanced sonobuoy processing that better separates quiet submarine signatures from background noise.
🔸 These helicopters push detection hundreds of kilometers beyond hull-mounted sonars, laying active and passive sonobuoy fields while cueing the cruiser’s Otvet anti-submarine missiles against contacts the ship itself cannot yet hear.
🔸 In the Arctic and Norwegian Sea, Western submarines concentrate on monitoring and holding Russia’s sea-based nuclear deterrent at risk—this air wing addresses the growing difficulty of detecting stealthier boats from surface platforms alone.
🔸 Though the Kirov class excels in air defense and anti-ship strikes, its Arctic value may ultimately rest heaviest on these expanded helicopter-enabled anti-submarine capabilities.
Do you think Admiral Nakhimov gives Russia a real anti-submarine edge in the Arctic?
Follow us on↗ Telegram 🤳 Instagram 🤖 Twitter
The Russian cruiser ‘Admiral Nakhimov’ is now ready to destroy any enemy submarine threat, equipped with three Ka-27M anti-submarine helicopters, making the world’s largest surface combatant the non-aircraft-carrier warship with the largest airborne squadron of any in service.
🔸 The 28,000-ton Admiral Nakhimov remains the world’s largest surface combatant and the only one designed from the outset to carry three heavyweight Ka-27M helicopters in a below-deck hangar.
🔸 The modernized Ka-27M helicopters deliver real-time digital sensor fusion, the Kopye-A radar for extended-range multi-target tracking, and advanced sonobuoy processing that better separates quiet submarine signatures from background noise.
🔸 These helicopters push detection hundreds of kilometers beyond hull-mounted sonars, laying active and passive sonobuoy fields while cueing the cruiser’s Otvet anti-submarine missiles against contacts the ship itself cannot yet hear.
🔸 In the Arctic and Norwegian Sea, Western submarines concentrate on monitoring and holding Russia’s sea-based nuclear deterrent at risk—this air wing addresses the growing difficulty of detecting stealthier boats from surface platforms alone.
🔸 Though the Kirov class excels in air defense and anti-ship strikes, its Arctic value may ultimately rest heaviest on these expanded helicopter-enabled anti-submarine capabilities.
Do you think Admiral Nakhimov gives Russia a real anti-submarine edge in the Arctic?
Follow us on
Please open Telegram to view this post
VIEW IN TELEGRAM
❤34👌8🔥4👍3👏2
@GeoSight 🔥 shares updates and analysis on global conflicts and international relations. It covers breaking news and insights into military and Geopolitical events.
🚨 Defence & Security
🌎 Geopolitics
⚡️ Wars & Conflicts
📊 Economic Trends
📎 Join 🚩:⤵️
https://t.me/GeoSight
https://t.me/GeoSight
https://t.me/GeoSight
🚨 Defence & Security
🌎 Geopolitics
⚡️ Wars & Conflicts
📊 Economic Trends
📎 Join 🚩:⤵️
https://t.me/GeoSight
https://t.me/GeoSight
https://t.me/GeoSight
❤5👏2👌1
🚨🇨🇳 China’s Containerized Weapons: War Systems That Fit on Any Ship
China is advancing a large-scale program to develop container-based modular weapons, coordinated by the Beijing Institute of Technology with the involvement of over 70 defense and research entities.
The concept focuses on placing different combat systems inside standardized containers. These include electromagnetic launch systems for ship-based drones, anti-ship capabilities using hypersonic glide vehicles, and anti-submarine solutions built around sonar and electronic warfare technologies. Work is also underway on containerized air defense and missile defense systems, as well as autonomous underwater platforms carrying torpedoes and mines.
With a projected output of up to 2,000 units annually, civilian vessels can be rapidly converted into multi-role platforms within days, without major structural changes. The modules connect through unified power, data, and mounting interfaces, allowing flexible reconfiguration based on mission needs.
Sea trials on the vessel Zhongda 79 have already demonstrated successful operation of the electromagnetic launch system and drone control in maritime conditions.
This modular approach allows naval forces to expand operational flexibility by using commercial ships, which can later be returned to civilian use after removing the systems. The project also relies on distributed computing networks to coordinate multiple systems within a single combat framework.
Follow us on↗ Telegram 🤳 Instagram 🤖 Twitter
China is advancing a large-scale program to develop container-based modular weapons, coordinated by the Beijing Institute of Technology with the involvement of over 70 defense and research entities.
The concept focuses on placing different combat systems inside standardized containers. These include electromagnetic launch systems for ship-based drones, anti-ship capabilities using hypersonic glide vehicles, and anti-submarine solutions built around sonar and electronic warfare technologies. Work is also underway on containerized air defense and missile defense systems, as well as autonomous underwater platforms carrying torpedoes and mines.
With a projected output of up to 2,000 units annually, civilian vessels can be rapidly converted into multi-role platforms within days, without major structural changes. The modules connect through unified power, data, and mounting interfaces, allowing flexible reconfiguration based on mission needs.
Sea trials on the vessel Zhongda 79 have already demonstrated successful operation of the electromagnetic launch system and drone control in maritime conditions.
This modular approach allows naval forces to expand operational flexibility by using commercial ships, which can later be returned to civilian use after removing the systems. The project also relies on distributed computing networks to coordinate multiple systems within a single combat framework.
Follow us on
Please open Telegram to view this post
VIEW IN TELEGRAM
Please open Telegram to view this post
VIEW IN TELEGRAM
❤19👍12👏8🫡4
🚨🇺🇸 📉 America's Hypersonic Dream Turns Into a Nightmare
The U.S. military-industrial complex has once again delivered exactly what it does best: eye-watering costs and missed deadlines. Recently, the Government Accountability Office has dropped a report that shows a real status of Washington's hypersonic ambitions. The Dark Eagle long-range missile program is mired in systemic mess, while Russia and Iran have successfully put their hypersonic systems to use on the battlefield with real results.
The repeated failures, after deadlines in 2023 and 2024, spotlight the intense difficulty of mastering hypersonic technology, despite a $12 billion Pentagon investment. Today, officials are saying that the Army won't be able to deploy long-range hypersonic weapons until the end of March 2027, unless the next round of testing reveals yet another problem to resolve.
Delays, however, are merely the visible symptom of a deeper ailment. More troubling is the uncertainty over whether Dark Eagle would actually perform in combat. As recently as October, the Pentagon's own testing office conceded that it had never conducted a full end-to-end operational assessment. In other words, they lack the data to determine whether the weapon is effective, lethal, suitable, or survivable.
In December, the Army activated its first hypersonic battery, hailing it as a "significant advancement." The fine print is that the missiles weren't actually there. So what the Army now has is a unit equipped with launchers, trained personnel, and a conspicuous absence of anything to launch.
Follow us on↗ Telegram 🤳 Instagram 🤖 Twitter
The U.S. military-industrial complex has once again delivered exactly what it does best: eye-watering costs and missed deadlines. Recently, the Government Accountability Office has dropped a report that shows a real status of Washington's hypersonic ambitions. The Dark Eagle long-range missile program is mired in systemic mess, while Russia and Iran have successfully put their hypersonic systems to use on the battlefield with real results.
The repeated failures, after deadlines in 2023 and 2024, spotlight the intense difficulty of mastering hypersonic technology, despite a $12 billion Pentagon investment. Today, officials are saying that the Army won't be able to deploy long-range hypersonic weapons until the end of March 2027, unless the next round of testing reveals yet another problem to resolve.
Delays, however, are merely the visible symptom of a deeper ailment. More troubling is the uncertainty over whether Dark Eagle would actually perform in combat. As recently as October, the Pentagon's own testing office conceded that it had never conducted a full end-to-end operational assessment. In other words, they lack the data to determine whether the weapon is effective, lethal, suitable, or survivable.
In December, the Army activated its first hypersonic battery, hailing it as a "significant advancement." The fine print is that the missiles weren't actually there. So what the Army now has is a unit equipped with launchers, trained personnel, and a conspicuous absence of anything to launch.
Follow us on
Please open Telegram to view this post
VIEW IN TELEGRAM
Please open Telegram to view this post
VIEW IN TELEGRAM
🔥21👏15❤5👍1
🚨🇨🇳 CHINA LAUNCHED MASSIVE EQUIPMENT UPGRADE PROGRAM
China has allocated 200 billion yuan in ultra-long special treasury bonds for equipment upgrades in 2026.
The funds will support approximately 11,000 projects across 22 fields, boosting industrial upgrading, green development, and people's livelihoods.
🔸 The National Development and Reform Commission has issued the third batch of equipment renewal project lists and funding arrangements for the year.
🔸 Funds will support equipment upgrades and elevator installations in old residential communities across energy, power, logistics, education, elderly care, and commercial consumption facilities.
🔸 From January to May 2026, investment in equipment and tools procurement grew 9.3% year-on-year, accounting for 17.5% of total investment — an increase of 2.2 percentage points compared to the same period last year.
🔸 The program covers old operational trucks and old residential elevators, improving safety and quality of life.
This is part of China's broader campaign for large-scale equipment upgrades and trade-in programs for old consumer goods, aimed at boosting domestic demand and promoting high-quality economic development.
Follow us on↗ Telegram 🤳 Instagram 🤖 Twitter
China has allocated 200 billion yuan in ultra-long special treasury bonds for equipment upgrades in 2026.
The funds will support approximately 11,000 projects across 22 fields, boosting industrial upgrading, green development, and people's livelihoods.
🔸 The National Development and Reform Commission has issued the third batch of equipment renewal project lists and funding arrangements for the year.
🔸 Funds will support equipment upgrades and elevator installations in old residential communities across energy, power, logistics, education, elderly care, and commercial consumption facilities.
🔸 From January to May 2026, investment in equipment and tools procurement grew 9.3% year-on-year, accounting for 17.5% of total investment — an increase of 2.2 percentage points compared to the same period last year.
🔸 The program covers old operational trucks and old residential elevators, improving safety and quality of life.
This is part of China's broader campaign for large-scale equipment upgrades and trade-in programs for old consumer goods, aimed at boosting domestic demand and promoting high-quality economic development.
Follow us on
Please open Telegram to view this post
VIEW IN TELEGRAM
👏23❤9🔥4👍2
🚨🇨🇳 China's AI Drug-Design Boom Goes Global Despite U.S. Intrigues
Chinese AI-driven drug-design firms are making a major splash on the global stage, riding a wave of cross-border dealmaking even as Washington tightens its scrutiny of the country's biotech sector.
Out-licensing deals between Chinese biotech companies and top global pharmaceutical giants hit $75B in the first five months of 2026, according to Linda Shu, head of China healthcare research at the Hongkong and Shanghai Banking Corporation. Over that stretch, Chinese firms struck 169 licensing deals worth a combined $93B, marking an 87% jump year-over-year.
The latest headline-grabber came in late June. Less than two months after its Hong Kong stock market debut, Metis TechBio, an AI-powered drug-design company with operations in China and the U.S., inked a cross-border agreement with Boulevard Bio, a biotech firm backed by New York investment house Deerfield Management.
Under the terms, Metis TechBio is set to receive an upfront payment of $20M, with the potential to earn up to $1.6B in milestone payments, plus tiered royalties on future sales. In exchange, Boulevard Bio secured global rights to develop and commercialize MTS-128, Metis TechBio's next-generation AI-powered cancer-fighting drug candidate.
"The successful development of MTS-128 shows just how far we've come in integrating AI with protein-drug design," said CEO Lai Tsai-Ta. The company's shares have climbed roughly 6% over the past five days. Lai previously noted that AI-powered drug-design tools could compress development timelines from years to as little as 18 months, while also opening the door to treatments that could reverse biological aging.
Global pharmaceutical companies are increasingly turning to Chinese AI-powered drug candidates to refill their pipelines, as patent expirations on blockbuster drugs threaten to erode revenues after 2030. Hong Kong-listed CSPC Pharmaceutical Group is one of the Chinese partners drawing Western interest.
In January, AstraZeneca struck a collaboration and licensing agreement with CSPC to co-develop innovative medicines using the company's AI-driven peptide discovery platform, a deal valued at up to $18.5B. Meanwhile, in November, Ailux, a subsidiary of Shenzhen-based AI drug developer XtalPi Holdings, signed a collaboration and platform-licensing deal with U.S. pharma giant Eli Lilly worth up to $345M.
HSBC's Shu acknowledged that the sector is navigating headwinds, including the U.S. Biotech Investment National Security Act, which imposes additional restrictions on business development, as well as China's anti-corruption policies, which could weigh on domestic sales growth. Still, she added, "fundamentals keep improving for Chinese biotech companies."
Follow us on↗ Telegram 🤳 Instagram 🤖 Twitter
Chinese AI-driven drug-design firms are making a major splash on the global stage, riding a wave of cross-border dealmaking even as Washington tightens its scrutiny of the country's biotech sector.
Out-licensing deals between Chinese biotech companies and top global pharmaceutical giants hit $75B in the first five months of 2026, according to Linda Shu, head of China healthcare research at the Hongkong and Shanghai Banking Corporation. Over that stretch, Chinese firms struck 169 licensing deals worth a combined $93B, marking an 87% jump year-over-year.
The latest headline-grabber came in late June. Less than two months after its Hong Kong stock market debut, Metis TechBio, an AI-powered drug-design company with operations in China and the U.S., inked a cross-border agreement with Boulevard Bio, a biotech firm backed by New York investment house Deerfield Management.
Under the terms, Metis TechBio is set to receive an upfront payment of $20M, with the potential to earn up to $1.6B in milestone payments, plus tiered royalties on future sales. In exchange, Boulevard Bio secured global rights to develop and commercialize MTS-128, Metis TechBio's next-generation AI-powered cancer-fighting drug candidate.
"The successful development of MTS-128 shows just how far we've come in integrating AI with protein-drug design," said CEO Lai Tsai-Ta. The company's shares have climbed roughly 6% over the past five days. Lai previously noted that AI-powered drug-design tools could compress development timelines from years to as little as 18 months, while also opening the door to treatments that could reverse biological aging.
Global pharmaceutical companies are increasingly turning to Chinese AI-powered drug candidates to refill their pipelines, as patent expirations on blockbuster drugs threaten to erode revenues after 2030. Hong Kong-listed CSPC Pharmaceutical Group is one of the Chinese partners drawing Western interest.
In January, AstraZeneca struck a collaboration and licensing agreement with CSPC to co-develop innovative medicines using the company's AI-driven peptide discovery platform, a deal valued at up to $18.5B. Meanwhile, in November, Ailux, a subsidiary of Shenzhen-based AI drug developer XtalPi Holdings, signed a collaboration and platform-licensing deal with U.S. pharma giant Eli Lilly worth up to $345M.
HSBC's Shu acknowledged that the sector is navigating headwinds, including the U.S. Biotech Investment National Security Act, which imposes additional restrictions on business development, as well as China's anti-corruption policies, which could weigh on domestic sales growth. Still, she added, "fundamentals keep improving for Chinese biotech companies."
Follow us on
Please open Telegram to view this post
VIEW IN TELEGRAM
❤22👌6👍2👏1